Respiratory syncytial virus vaccine adjuvanted - GSK
Alternative Names: AREXVY; Arexvy; GSK-3844766; GSK-3844766A; Respiratory syncytial virus vaccine, adjuvanted - GlaxoSmithKline; RSV vaccine, Adjuvanted - GSK; RSV_PreF3 Vaccine; RSVPreF3 OA; RSVPreF3 OA vaccineLatest Information Update: 20 Aug 2024
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Respiratory syncytial virus vaccines; Subunit vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Respiratory syncytial virus infections
Most Recent Events
- 05 Aug 2024 Phase-III clinical trials in Respiratory syncytial virus infections (In adults, In the elderly, Prevention) in Spain (IM) (NCT06551181)
- 05 Aug 2024 GlaxoSmithKline initiates a phase III trial for Respiratory syncytial virus infections (In adults, In the elderly, Prevention) in the United Kingdom (IM) (NCT06551181)
- 01 Aug 2024 Phase-III clinical trials in Respiratory syncytial virus infections (In the elderly, Prevention) in USA, Japan (IM) (NCT06534892)